{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:51:07Z","timestamp":1791280267231,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["SFRH\/BD\/43399\/2008"],"award-info":[{"award-number":["SFRH\/BD\/43399\/2008"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["SFRH\/BPD\/66288\/2009"],"award-info":[{"award-number":["SFRH\/BPD\/66288\/2009"]}]},{"name":"European Social Fund (ESF)"},{"name":"National Strategic Reference Framework (NSRF)"},{"name":"Portuguese League Against Cancer (LPCC-NRNorte)"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2015,11]]},"abstract":"\n Objective<\/jats:title>\n \n To evaluate the predictive value of genetic polymorphisms in the context of bacille\n C<\/jats:styled-content>\n almette\u2010\n G<\/jats:styled-content>\n u\u00e9rin (\n BCG<\/jats:styled-content>\n ) immunotherapy outcome and create a predictive profile that may allow discrimination of the risk of recurrence.\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n In a dataset of 204 patients treated with\n BCG<\/jats:styled-content>\n , we evaluated 42 genetic polymorphisms in 38 genes involved in the\n BCG<\/jats:styled-content>\n mechanism of action, using Sequenom\n MassARRAY<\/jats:styled-content>\n \u00ae<\/jats:sup>\n technology. Stepwise multivariate\n C<\/jats:styled-content>\n ox regression was used for data mining.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In agreement with previous studies we found that gender, age, tumour multiplicity and treatment scheme were associated with\n BCG<\/jats:styled-content>\n failure. Using stepwise multivariate\n C<\/jats:styled-content>\n ox regression analysis we propose the first predictive profile of\n BCG<\/jats:styled-content>\n immunotherapy outcome and a risk score based on polymorphisms in immune system molecules [single nucleotide polymorphisms in tumour necrosis factor \u03b1 (\n TNFA<\/jats:styled-content>\n )\u20101031\n T<\/jats:styled-content>\n \/\n C<\/jats:styled-content>\n (rs1799964), interleukin 2 receptor \u03b1 (\n IL2RA<\/jats:styled-content>\n ) rs2104286\n T<\/jats:styled-content>\n \/\n C<\/jats:styled-content>\n ,\n IL17A<\/jats:styled-content>\n \u2010197\n G<\/jats:styled-content>\n \/\n A<\/jats:styled-content>\n (rs2275913),\n IL17RA<\/jats:styled-content>\n \u2010809\n A<\/jats:styled-content>\n \/\n G<\/jats:styled-content>\n (rs4819554),\n IL18R1<\/jats:styled-content>\n rs3771171\n T<\/jats:styled-content>\n \/\n C<\/jats:styled-content>\n , intercellular adhesion molecule 1 (\n ICAM<\/jats:styled-content>\n \u20101)\n K469E<\/jats:styled-content>\n (rs5498), Fas ligand (\n FASL<\/jats:styled-content>\n )\u2010844T\/\n C<\/jats:styled-content>\n (rs763110) and\n TNF<\/jats:styled-content>\n \u2010related apoptosis\u2010inducing ligand receptor 1 (\n TRAILR1<\/jats:styled-content>\n )\u2010397\n T<\/jats:styled-content>\n \/\n G<\/jats:styled-content>\n (rs79037040)] in association with clinicopathological variables. This risk score allows the categorisation of patients into risk groups: patients within the low\u2010risk group have a 90% chance of successful treatment, whereas patients in the high\u2010risk group present a 75% chance of recurrence after\n BCG<\/jats:styled-content>\n treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n We have established the first predictive score of\n BCG<\/jats:styled-content>\n immunotherapy outcome combining clinicopathological characteristics and a panel of genetic polymorphisms. Further studies using an independent cohort are warranted. Moreover, the inclusion of other biomarkers may help to improve the proposed model.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12844","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T20:23:37Z","timestamp":1402950217000},"page":"753-763","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The role of functional polymorphisms in immune response genes as biomarkers of bacille\n C<\/scp>\n almette\u2010\n G<\/scp>\n u\u00e9rin (\n BCG<\/scp>\n ) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a\n S<\/scp>\n outhern\n E<\/scp>\n urope population"],"prefix":"10.1111","volume":"116","author":[{"given":"Lu\u00eds","family":"Lima","sequence":"first","affiliation":[{"name":"Experimental Pathology and Therapeutics Group Portuguese Institute of Oncology Porto Portugal"},{"name":"ICBAS Abel Salazar Biomedical Sciences Institute University of Porto Porto Portugal"},{"name":"Nucleo de Investiga\u00e7\u00e3o em Farm\u00e1cia \u2013 Centro de Investiga\u00e7\u00e3o em Sa\u00fade e Ambiente (CISA) School of Allied Health Sciences \u2013 Polytechnic Institute of Oporto Porto Portugal"},{"name":"LPCC Research Department\u2010Portuguese League Against Cancer (NRNorte) Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Experimental Pathology and Therapeutics Group Portuguese Institute of Oncology Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Experimental Pathology and Therapeutics Group Portuguese Institute of Oncology Porto Portugal"},{"name":"Mass Spectrometry Center of the University of Aveiro Aveiro Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Tavares","sequence":"additional","affiliation":[{"name":"Experimental Pathology and Therapeutics Group Portuguese Institute of Oncology Porto Portugal"},{"name":"Department of Pathology Portuguese Institute of Oncology Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Cruz","sequence":"additional","affiliation":[{"name":"Department of Urology Portuguese Institute of Oncology Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"LPCC Research Department\u2010Portuguese League Against Cancer (NRNorte) Porto Portugal"},{"name":"Molecular Oncology Group Portuguese Institute of Oncology Porto Portugal"},{"name":"Department of Pathology and Molecular Immunology University of Porto Porto Portugal"},{"name":"Health Faculty of University Fernando Pessoa Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facio","family":"Santos","sequence":"additional","affiliation":[{"name":"Experimental Pathology and Therapeutics Group Portuguese Institute of Oncology Porto Portugal"},{"name":"Health Faculty of University Fernando Pessoa Porto Portugal"},{"name":"Department of Surgical Oncology Portuguese Institute of Oncology Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0395-z"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.003"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.05.027"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.017"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.32"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116202"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602026"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2002.00415.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000073852.24341.4a"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/181987"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20640"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.06.005"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-009-9195-6"},{"key":"e_1_2_7_16_1","first-page":"3729","article-title":"Perforin\u2010mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette\u2010Guerin\u2010activated killer cells","volume":"6","author":"Brandau S","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/232609"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.6.6.575"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.05.009"},{"key":"e_1_2_7_20_1","unstructured":"OosterlinckW van derMeijdenA SylvesterRet\u2009al.Guidelines on TaT1 (Non\u2010muscle invasive) bladder cancer. EAU guidelines 2006. Available at:http:\/\/www.uroweb.org\/gls\/pdf\/05%20Non-muscle%20Invasive%20BC_TaT1_LR.pdf. Accessed December 2014"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4501002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.09.026"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.10.012"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.571"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000331882"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08549.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2010.03.005"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2013.01.025"},{"key":"e_1_2_7_30_1","first-page":"91","article-title":"Soluble intercellular adhesion molecule\u20101 (sICAM\u20101): an overview","volume":"15","author":"Witkowska AM","year":"2004","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.12.7224"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.147.12.4398"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.02.018"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040773"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mc.21992"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37938"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03191.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2008.0027"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.8.4646"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.10.028"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2008.11.009"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2009.05258.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.598"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2008.02.015"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12844","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:38:02Z","timestamp":1761748682000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/bju.12844"],"URL":"https:\/\/doi.org\/10.1111\/bju.12844","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]},"assertion":[{"value":"2015-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}